AJP - Heart Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 289: H1176-H1183, 2005. First published May 6, 2005; doi:10.1152/ajpheart.00088.2005
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/3/H1176    most recent
00088.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cowling, R. T.
Right arrow Articles by Greenberg, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cowling, R. T.
Right arrow Articles by Greenberg, B. H.

Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts

Randy T. Cowling,1 Xiaowei Zhang,1 Vanessa C. Reese,1 Michikado Iwata,1 Devorah Gurantz,1 Wolfgang H. Dillmann,2 and Barry H. Greenberg1

Department of Medicine, Divisions of 1Cardiology and 2Endocrinology, University of California, San Diego, California

Submitted 28 January 2005 ; accepted in final form 4 May 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Angiotensin II (ANG II) plays important roles in cardiac extracellular matrix remodeling via its type 1A (AT1A) receptor. The cytokines tumor necrosis factor-{alpha} and interleukin-1{beta} (IL-1{beta}) were shown previously to upregulate AT1A receptor mRNA and protein, thereby increasing the profibrotic response to ANG II in cardiac fibroblasts. The present experiments implicate increased nuclear factor-{kappa}B (NF-{kappa}B)-dependent transcription and also, to a lesser extent, altered mRNA splicing in the mechanism of receptor upregulation. Cytokine stimulation was found to increase AT1A heterogeneous nuclear RNA levels, which strongly suggests that mRNA upregulation occurs transcriptionally. The transcription factor NF-{kappa}B was previously deemed necessary for cytokine-induced AT1A receptor mRNA upregulation. Computer analysis of upstream DNA sequences revealed putative NF-{kappa}B elements at –365 and –2540 bp. Both isolated elements were shown to bind NF-{kappa}B (using gel-shift assays) and to transactivate a minimal promoter (using reporter assays), although the element at –365 bp appeared stronger. Three splice variants of AT1A receptor mRNA that have different 5' untranslated regions were detected in rat tissues, namely, exons 1-2-3 (predominant), 1-2-3+6, and 1-3. Cytokine treatment of fibroblasts upregulated all splice variants, but exon 1-3 increased more than the others. This differential upregulation, albeit of modest magnitude, was statistically significant with IL-1{beta} treatment. Exon 2 contains an inhibitory minicistron and a predicted inhibitory hairpin structure. Luciferase reporter assays indicated that each splice variant translates at a different efficiency, with exon 1-2-3+6 (both minicistron and hairpin) < exon 1-2-3 (minicistron only) < exon 1-3 (neither minicistron or hairpin). These results provide evidence that cytokines increase AT1 protein levels by altering both transcription and splicing.

messenger RNA; heart; nuclear factor-{kappa}B; tumor necrosis factor-{alpha}; interleukin-1 {beta}

ANGIOTENSIN II (ANG II), the main active peptide of the renin-angiotensin system, plays an important role in regulating the cardiovascular and renal systems during health and in a variety of disease states. Two major receptors exist for ANG II that are designated type 1 and type 2 (AT1 and AT2, respectively). Most of the known biological functions of ANG II can be attributed to AT1 receptors, whereas AT2 receptors tend to act antagonistically when expressed (12, 23). Mice and rats possess two isoforms of AT1 receptors (AT1A and AT1B) that function similarly but are encoded on different chromosomal regions (3). Rat AT1A receptors, which are the most widely studied, are encoded on chromosome 17q12 and consist of three exons interspaced by two large introns. Exons 1 and 2 represent the 5' untranslated region (UTR), and exon 3 encodes the full open reading frame (ORF; Ref. 34). Encoding of the entire ORF on the final exon is a characteristic of AT1 receptors that is conserved between rats and humans (5, 34).

Postmyocardial infarction (post-MI) remodeling of the extracellular matrix (ECM) includes formation of a replacement scar at the infarct site and deposition of fibrous tissue in noninfarcted myocardium (1). Proper formation of a replacement scar is necessary to maintain structural integrity of the heart. Fibrosis in noninfarcted regions of myocardium, however, can both increase diastolic stiffness and cause contractile dysfunction (2). ANG II is elevated in the hearts of animals with experimentally induced MI (38). Administration of angiotensin-converting enzyme (ACE) inhibitors or AT1 antagonists inhibits adverse ECM remodeling and reduces mortality in these animals (7, 20, 28, 37). ACE inhibitors also increase survival of humans after MI (29). In experimental animals, chronic elevation of circulating ANG II levels alone has been shown to lead to interstitial fibrosis of myocardium (33). In addition, stimulation of cultured rat cardiac fibroblasts with ANG II can lead to increased proliferation, synthesis of ECM proteins, and secretion of profibrotic factors such as transforming growth factor-{beta} (17, 30, 35), which are effects related to activation of AT1A receptors.

Increased AT1 receptor density has been demonstrated near the infarction zone and in noninfarcted regions of myocardium after MI (18, 25). Proinflammatory cytokines such as tumor necrosis factor-{alpha} (TNF-{alpha}) and interleukin-1{beta} (IL-1{beta}) are increased in rat heart after experimental MI (15, 26) and have been shown to colocalize with AT1 receptors on nonmyocytes (10). We have demonstrated previously that AT1 receptor mRNA and protein are upregulated in cultured neonatal rat cardiac fibroblasts by TNF-{alpha} and IL-1{beta} (11). Because increased AT1 receptor density enhances fibroblast functions that favor fibrosis (27), cytokine-induced upregulation of AT1 receptor mRNA and protein appears to be an important determinant of ECM remodeling after MI. Thus determining the mechanisms and signaling pathways involved in AT1 upregulation by TNF-{alpha} and IL-1{beta} would further our understanding of post-MI ECM remodeling and could provide insights toward new approaches for treatment.

We have previously shown (4) that the transcription factor nuclear factor-{kappa}B (NF-{kappa}B) is necessary for cytokine-induced AT1 mRNA upregulation. The present studies were performed to determine how proinflammatory cytokines and NF-{kappa}B increase the level of AT1A receptors in rat cardiac fibroblasts. Our findings indicate that cytokine stimulation increases transcription of AT1A through a mechanism that appears to involve two NF-{kappa}B binding sites within the 5' flanking region of the gene. Cytokine treatment also alters AT1A mRNA splicing, which results in the preferential increase of a splice variant that is translated more efficiently than the others. Thus cytokines increase AT1 receptor levels mainly by increasing transcription but also by altering mRNA splicing.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cultured cells. Animal protocols were approved and monitored by the Institutional Animal Care and Use Committee of the University of California, San Diego. Rat cardiac fibroblasts were isolated and maintained as described previously (4). The 293A cells used in this study were purchased from Invitrogen and were grown under the same conditions as the fibroblasts. In some experiments that involved general cellular processes (e.g., inhibition of translation by a minicistron), 293A cells were used because they could be transfected more readily than primary fibroblasts.

RT-PCR for AT1A heterogeneous nuclear RNA. Total RNA was isolated from confluent neonatal rat cardiac fibroblasts using an RNeasy kit (Qiagen) and was then digested with RNase-free DNase I. Concentration of RNA was determined by measuring absorbance at 260 nm. RT-PCR was performed on 100 ng of total RNA using the Titan One Tube RT-PCR System (Roche Applied Science) following the manufacturer's instructions. Primers were chosen to amplify AT1A heterogeneous nuclear RNA (hnRNA; across the exon 1-intron I junction and across the intron II-exon 3 junction), AT1A mRNA (across the exon 2-exon 3 junction), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (see Table 1, nos. 10–17). PCR cycling parameters were as follows: 50°C for 30 min (1 cycle); 94°C for 2 min (1 cycle); 94°C for 30 s, 55°C for 30 s, 68°C for 45 s (10 cycles then x cycles, with a 5-s elongation increment per cycle, where x = 5 for mRNA and x = 10 for hnRNA); and 68°C for 7 min. PCR reactions were purified with a QIAquick PCR Purification Kit (Qiagen), brought to 0.4 N NaOH and 10 mM EDTA, and heated at 95°C for 10 min. Denatured samples were slotted onto a charged nylon membrane (Magnacharge; GE Osmonics; Minnetonka, MN) using a Bio-Dot SF (slot format) slot-blotting apparatus (Bio-Rad Laboratories). Membranes were incubated at 65°C in prehybridization solution (5x sodium chloride-sodium phosphate-EDTA, 5x Denhardt's solution, 0.5% SDS, and 15 µg/ml sheared heat-denatured salmon DNA) for several hours in roller bottles. The PCR fragment corresponding to that slotted onto the membrane was labeled with 32P (using a Megaprime DNA-labeling system from Amersham Biosciences), heat denatured, and added to the roller bottle. The hybridization was allowed to proceed overnight. Membranes were washed three times at lower stringency (2x SSC and 0.1% SDS at 42°C for 15 min per wash) and three times at higher stringency (0.2x SSC and 0.1% SDS at 50°C for 15 min/wash). Damp membranes were exposed to a storage phosphor screen and then visualized on a Storm 860 fluorescent scanner (Molecular Dynamics; Sunnyvale, CA). Signal intensities were quantified using the software supplied with the scanner (ImageQuant).


View this table:
[in this window]
[in a new window]
  		Table 1. Synthetic oligodeoxyribonucleotides

 
RT-PCR for AT1A splice variants. Total RNA was isolated from various rat tissues and cultured cells as described. RT-PCR was performed on 100 ng of total RNA. Primers were chosen to amplify AT1A mRNA across exon 2 (Table 1, nos. 18 and 19). PCR cycling parameters were as follows: 50°C for 30 min (1 cycle); 94°C for 2 min (1 cycle); 94°C for 30 s, 53°C for 30 s, and 68°C for 45 s (10 cycles then 15 cycles with a 5-s elongation increment per cycle); and 68°C for 7 min. PCR reactions were purified with a QIAquick PCR Purification Kit and electrophoresed on a 12% polyacrylamide gel (Mini-Protean II; Bio-Rad) in 40 mM Tris acetate with 1 mM EDTA until the bromophenol blue tracking dye exited the bottom of the gel. The gel was stained for 30 min in 40 mM Tris acetate with 1 mM EDTA and Vistra Green nucleic acid gel stain (Amersham Biosciences) and then visualized on the Storm 860 fluorescent scanner.

Electrophoretic mobility shift assay. Gel-shift assays were performed as described previously (4). Briefly, double-stranded synthetic oligodeoxyribonucleotides were radiolabeled with T4 polynucleotide kinase and [{gamma}-32P]ATP and purified with a QIAquick Nucleotide Removal Kit (Qiagen). Three oligonucleotides were used that correspond to the NF-{kappa}B consensus sequence in the B cell {kappa}-light-chain enhancer region and the putative NF-{kappa}B binding sequences at –365 and –2540 bp of the rat AT1A gene (for sequence of upper strands, see Table 1, nos. 1–3). Nuclear extract from confluent neonatal rat cardiac fibroblasts (2 µg of protein) was incubated with the radiolabeled probe. Bound probe and free probe were separated by electrophoresis on a nondenaturing polyacrylamide gel. The gel was dried and exposed to film (Kodak BioMax MS) or to a storage phosphor screen.

Cell transfection. The 293A cells (3 x 105 cells/well) were plated in a six-well dish and allowed to grow overnight. Cells were then transfected using FuGENE 6 Transfection Reagent (Roche Applied Science) according to the manufacturer's instructions. Reagent amounts used per well were 0.25 µg of pgk-lacZ (to normalize transfection efficiencies; kindly provided by Dr. Michael McBurney, University of Ottawa, Ontario, Canada), 0.25 µg of luciferase reporter plasmid, 1.5 µl of FuGENE 6, and 2 ml of serum-containing DMEM. Cells were allowed to transfect for 24 h and then were treated with cytokine if indicated. Neonatal rat cardiac fibroblasts were transfected using essentially the same procedure except that to improve transfection efficiency, 2 x 105 cells/well were plated, and the amounts of plasmid and FuGENE were doubled.

Reporter assays. Cell lysates were assayed for {beta}-galactosidase and luciferase activity essentially as described by Guo et al. (9). Lysates from untransfected cells were also assayed, and the resulting absorbance values were subtracted from all values as background. The {beta}-galactosidase activity was calculated as milliunits per microliter of cell lysate, where one milliunit hydrolyzed 1 nmol 2-nitrophenyl {beta}-D-galactopyranoside per minute at 37°C. Luciferase activity was calculated as relative light units per microliter of cell lysate and was normalized to {beta}-galactosidase activity.

Construction of reporter plasmids. Reporters consisting of six tandem NF-{kappa}B elements upstream of a minimal SV-40 promoter driving luciferase were derived from the plasmid pGL3-Promoter (Promega; Madison, WI). Complimentary synthetic oligodeoxyribonucleotides consisting of 6x {kappa}B, 6x –365, or 6x –2540 elements (Table 1, nos. 4–9) were annealed and then ligated into the SmaI-BglII sites of pGL3-Promoter. Chemically competent JM109 Escherichia coli were transformed with ligation mixtures, and plasmid clones were screened for the presence of the EcoRI restriction site arising from the synthetic DNA.

For AT1A 5' UTR sequences, both a BstXI and an EcoRV site were inserted between the transcriptional and translational start sites of the luciferase gene in the vector pGL3-Promoter by ligation of a synthetic linker adapter (formed by annealing oligonucleotides nos. 20 and 21 from Table 1) into the HindIII and NcoI sites of the vector. AT1A 5' UTR sequences (from the start of transcription to immediately before the start codon) were amplified from rat RNA using the Titan One Tube RT-PCR System (for primers, see Table 1, nos. 22 and 23). PCR cycling parameters were as follows: 50°C for 30 min (1 cycle); 94°C for 2 min (1 cycle); 94°C for 30 s, 50°C for 30 s, 68°C for 30 s (10 cycles, then 25 cycles with a 5-s elongation increment per cycle); and 68°C for 7 min. The PCR fragments were ligated into the TA cloning vector pCR2.1 (Invitrogen), and three clones were selected that represented the 1-2-3, 1-2-3+6, and 1-3 splice variants (see Fig. 5A for representative structures), all in the forward orientation. The inserts were excised by digestion with EcoRV and partial digestion with BstXI (to minimize cutting at the BstXI site within the AT1A 5' UTR) and then ligated into the BstXI-EcoRV sites of the modified pGL3-Promoter vector. Thus the entire AT1A 5' UTR was incorporated into the 5' UTR of the luciferase reporter gene, and there were three constructs in total, one for each of the AT1A splice variants.



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 5. Rat AT1A exon 2 minicistron reduces efficiency of translation of a luciferase reporter gene. The 5' UTR regions of the three corresponding rat AT1A splice variants (i.e., 1-3, 1-2-3, and 1-2-3+6) were amplified by RT-PCR and cloned between the promoter and start codon of the luciferase reporter vector pGL3-Promoter (Promega). Additionally, the two ATGs in the exon 2 minicistron of the 1-2-3 construct were removed by site-directed mutagenesis (i.e., Mut-1-2-3). A: schematics of these four luciferase reporter mRNAs. Sequences derived from AT1A exons 1 and 2 are depicted as light gray boxes. Minicistron in exon 2 starts with AUG and ends with UAA. Dark gray boxes, which would normally contain exon 3 and the entire AT1A open reading frame (ORF), now contain the luciferase ORF. B: each of the constructs was transfected into 293A cells along with another vector encoding LacZ. After 24 h, the cells were lysed and assayed for both luciferase and {beta}-galactosidase activity. Luciferase activities were normalized to that of {beta}-galactosidase and then plotted relative to the 1-3 value. Plotted values are means ± SE (n = 6 for 1-3 and 1-2-3; n = 3 for Mut-1-2-3 and 1-2-3+6). Values were compared using a one-way ANOVA and Tukey's multiple-comparison testing. *P < 0.001 vs. 1-3 value; NS, not significantly different from 1-3 value (P > 0.05); #P < 0.05 vs. 1-2-3 value.

 
To minimize the effect of lipopolysaccharide on cultured cells, selected plasmid clones were purified using an EndoFree Plasmid Maxi Kit (Qiagen).

Oligodeoxynucleotide-directed mutagenesis. Plasmid 1-2-3 (see Fig. 5A) was transformed into E. coli strain JM109 and rendered single stranded by infection with helper filamentous bacteriophage R408 (Promega). Approximately 50 ng of single-strand DNA was annealed to oligonucleotide no. 24 (Table 1) and then treated with 5 U of T4 DNA polymerase and 1 U of T4 DNA ligase in 20 mM Tris·HCl (pH 7.5), 0.5 mM dNTPs, 1 mM ATP, 2 mM DTT, 7 mM MgCl2, and 30 mM NaCl at 37°C for 90 min. The mixture was transformed into competent BMH 71-18mutS E. coli (Promega) and grown overnight in Luria-Bertani broth with 100 µg/ml ampicillin. The plasmid mixture was isolated from the culture, transformed into competent TOP10 E. coli (Invitrogen), and plated on Luria-Bertani agar with 100 µg/ml ampicillin. Single colonies were selected and screened for the presence of the newly generated PmeI restriction site. Thus both start codons in AT1A exon 2 were eliminated by point mutation, and the resulting mutant was termed Mut-1-2-3 (see Fig. 5A). Successful mutagenesis was verified by sequencing (DNA Sequencing Shared Resource; University of California, San Diego Cancer Center).


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Cytokines IL-1{beta} and TNF-{alpha} increase transcription of rat AT1A gene. We have previously demonstrated that the proinflammatory cytokines TNF-{alpha} and IL-1{beta} upregulate AT1A mRNA in neonatal rat cardiac fibroblasts (10, 11), a process that involves the transcription factor NF-{kappa}B (4). To provide additional evidence that this upregulation resulted from increased transcriptional activity, RT-PCR of AT1 hnRNA was performed (8, 14). Consistent with our previous findings, treatment of cardiac fibroblasts with TNF-{alpha} or IL-1{beta} increased AT1 mRNA levels as measured by amplifying from exon 2 to exon 3 (Fig. 1B, bottom). Cytokine treatment also increased AT1 hnRNA levels as measured by amplification across the exon 1-intron I junction and across the intron II-exon 3 junction (Fig. 1B, top). Amplimers were not detected in the absence of reverse transcription, and thus did not originate from contaminating DNA (data not shown). Cytokine treatment failed to alter GAPDH mRNA levels (using primers no. 16 and 17 from Table 1; data not shown), which indicates that the observed upregulations of AT1 RNA were not the result of a global alteration of RNA levels. Therefore, the finding that proinflammatory cytokines increase AT1 hnRNA levels along with previous evidence that TNF-{alpha} treatment did not alter AT1 mRNA stability (11) collectively indicate that AT1 upregulation occurs transcriptionally.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1. Treatment with TNF-{alpha} (T) or IL-1{beta} (IL) upregulates both angiotensin (ANG) II type 1A (AT1A) heterogeneous nuclear RNA (hnRNA) and messenger RNA (mRNA) in rat cardiac fibroblasts. A: schematic (not to scale) of rat AT1A hnRNA (top) and a spliced, mature mRNA (bottom). Exons 1, 2, and 3 are depicted as shaded boxes that are connected by straight lines representing introns I and II. Regions amplified by RT-PCR are indicated as i, ii, and iii. B: fibroblast cultures were stimulated with 1 ng/ml IL-1{beta} or 10 ng/ml TNF-{alpha}. Treatment times were chosen to maximize RNA increases (i.e., IL-1{beta}: 3 h for hnRNA, 8 h for mRNA; TNF-{alpha}: 6 h for hnRNA, 24 h for mRNA). Total RNA was isolated from cells and subjected to RT-PCR as described (see MATERIALS AND METHODS). Primers that amplified across the exon 1-intron I junction (amplimer i; primer nos. 10 and 11 in Table 1) and the intron II-exon 3 junction (amplimer ii; primer nos. 12 and 13 in Table 1) were utilized for hnRNA, whereas primers that amplified from exon 2 to exon 3 (amplimer iii; primer nos. 14 and 15 in Table 1) were used for mRNA. AT1A RNA levels are plotted as fold increases over the corresponding "no cytokine treatment" value (means ± SE; n = 3). No, no cytokine treatment.

 
Identification of rat AT1A start of transcription and upstream NF-{kappa}B binding sequences. To determine the region of the AT1A promoter used in rat neonatal cardiac fibroblasts, RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE; GeneRacer Kit; Invitrogen) was performed on total RNA from cultured cells. All 5' RACE PCR products started with the sequence 5'-TCCAGGCAGTTGGGA-3', which indicates that the start of transcription occurred 3 bp upstream of that previously reported for rat vascular smooth muscle, glial, and liver cells (21, 34). Therefore, the promoter region used in neonatal rat cardiac fibroblasts was identical to that published previously (GenBank accession no. S66402).

To identify putative NF-{kappa}B binding sites in the rat AT1A promoter region, we screened its known sequence (GenBank accession no. S66402) against the vertebrate matrix of the TRANSFAC database (13) using the TFSEARCH computer program (available at http://www.cbrc.jp/research/db/TFSEARCH.html) at a threshold score of 85.0. This screening identified two putative sites at –365 (5'-GGGAGTTCCC-3') and –2540 (5'-GGGGAAGCCC-3') bp. To verify qualitatively that these putative sites could bind NF-{kappa}B, electrophoretic mobility shift assays (EMSAs) were performed. Similar to that observed with the classical {kappa}B element (5'-GGGACTTTCC-3'), a band shift was observed with either putative sequence after treatment of cardiac fibroblasts with TNF-{alpha} or IL-1{beta} (Fig. 2A). To provide additional evidence of NF-{kappa}B binding, band shifts were competed with excess nonradiolabeled {kappa}B probe (Fig. 2B, {kappa}B, lane 3; –365, lane 8; and –2540, lane 13) and supershifted with an anti-p65 antibody (Fig. 2B, {kappa}B, lane 4; –365, lane 9; and –2540, lane 14); control antibody (i.e., rabbit IgG) did not supershift the bands (Fig. 2B, {kappa}B, lane 5; –365, lane 10; and –2540, lane 15). To demonstrate that these putative sequences could activate a promoter upon NF-{kappa}B binding, six identical elements were placed in tandem upstream of a minimal SV-40 promoter controlling luciferase expression. These plasmids were transfected into neonatal rat cardiac fibroblasts. Upon stimulation with cytokine, normalized luciferase activity increased with both the 6x 365- and 6x 2540-bp constructs, although the increase was much greater with 6x 365 bp (Fig. 3B). A similar trend was observed in transfected 293A cells, although the magnitude of response was greater than in primary fibroblasts (Fig. 3A). Therefore, EMSAs and reporter assays demonstrated that both sequences, when isolated, served as functional NF-{kappa}B binding sites.



View larger version (43K):
[in this window]
[in a new window]
  		Fig. 2. Sequences at –365 and –2540 bp of the rat AT1A gene bind nuclear factor (NF)-{kappa}B in electrophoretic mobility shift assay (EMSA). A: cultures of neonatal rat cardiac fibroblasts were untreated (No) or were stimulated with TNF-{alpha} (T; 50 ng/ml) or IL-1{beta} (IL; 1 ng/ml) for 1 h. Nuclear protein extracts were prepared and subjected to EMSA as described (see MATERIALS AND METHODS). Three radiolabeled probes were tested, namely, the classical {kappa}B consensus sequence and the putative NF-{kappa}B binding sequences at –365 and –2540 bp of the rat AT1A gene. B: nuclear extracts from cardiac fibroblasts stimulated with 50 ng/ml TNF-{alpha} for 3 h were subjected to another EMSA. To verify the specificity of the shift, binding was competed with excess nonradiolabeled {kappa}B probe (lanes 3, 8, and 13) and supershifted with an anti-p65 antibody (lanes 4, 9, and 14). Nonspecific rabbit IgG had no effect (lanes 5, 10, and 15). Nuclear extracts from fibroblasts stimulated with IL-1{beta} produced identical results. Note that nucleotide positions (i.e., –365 and –2540 bp) are labeled according to the transcriptional start site previously identified in vascular smooth muscle cells (34).

 


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 3. Sequences at –365 and –2540 bp of rat AT1A gene increase transcription from a minimal promoter upon NF-{kappa}B activation. Luciferase reporter plasmids that contain six tandem NF-{kappa}B binding elements upstream of a minimum SV-40 promoter were constructed as described (see MATERIALS AND METHODS). Cells (293A cells and neonatal rat cardiac fibroblasts) were cotransfected with the indicated luciferase reporter and a vector encoding LacZ to control for variations in transfection efficiency. At 24 h posttransfection, cells were stimulated without (open bars) or with (solid bars) 50 ng/ml of either recombinant human or rat TNF-{alpha} for 4 h. A: 293A cells stimulated with recombinant human TNF-{alpha}. B: neonatal rat cardiac fibroblasts stimulated with rat TNF-{alpha}. Cell extracts were prepared and assayed for luciferase and {beta}-galactosidase as described (see MATERIALS AND METHODS). Luciferase light units were normalized to {beta}-galactosidase activity and plotted as fold increases over "no cytokine" values (means ± SE; n = 3). Minimal SV40 is the parent vector, pGL3-Promoter (Promega), from which the other constructs were derived.

 
Identification of AT1A splice variants and differential upregulation by cytokines. While we performed RACE to identify the promoter region, it became apparent that more than one transcript size of AT1A mRNA existed. A higher-resolution separation of RT-PCR products spanning exon 1 to exon 3 revealed the expression of three splice variants (Fig. 4 A, top, lane 1). DNA sequencing of the two major PCR products demonstrated that the smaller amplimer represented exon 1-3, whereas the larger represented exon 1-2-3. In addition, there was a minor amplimer representing exon 1-2-3, where the splice-acceptor site in exon 3 had been shifted 6 bp upstream (Fig. 4A, top, exon 1-2-3+6). The variants differed in size by ≤89 bp (approximately the size of exon 2), which explains why they appeared as a single band on Northern blots. All rat tissues examined expressed the three variants with exon 1-2-3 predominating; the notable exception was brain tissue, where expression levels were low but exon 1-3 did appear more prevalent (Fig. 4A). The sequences of the splice variants were submitted to GenBank (accession nos. AY585652, AY585653, and AY585654).



View larger version (49K):
[in this window]
[in a new window]
  		Fig. 4. RT-PCR of AT1A 5' untranslated regions (UTRs) to identify splice variants. A: AT1A splice variants in rat cells and tissues. Total RNA was isolated from rat cells and tissues and subjected to RT-PCR as described (see MATERIALS AND METHODS). Bands representing the three AT1A splice variants are labeled (top). RT-PCR for GAPDH was also performed on the same samples to verify RNA integrity (bottom). Fib, cardiac ventricular fibroblast; Myo, ventricular cardiomyocyte. All other tissues were obtained from an adult male Sprague-Dawley rat. B: all three AT1A splice variants are upregulated by cytokine treatment. Total RNA was isolated from cultured neonatal rat cardiac fibroblasts treated with either IL-1{beta} (IL; 1 ng/ml for 8 h) or TNF-{alpha} (T; 50 ng/ml for 24 h) or no cytokine treatment (No) and subjected to RT-PCR. Positions of the three splice variants are indicated (right). C: smallest AT1A splice variant, exon 1-3, increases to a greater extent with cytokine treatment. The 1-3 and amalgamated (1-2-3 + 1-2-3+6) signals from B were quantified on the Storm 860 fluorescent scanner using ImageQuant software. The 1-3 value was multiplied by 1.392 to correct for its smaller mass. Ratio of the corrected 1-3 to the amalgamated 1-2-3 signal was plotted (mean ± SE; n = 6). Values were compared using one-way ANOVA and subsequent Dunnett's multiple-comparison testing. *P < 0.01, significantly different from "No" value; NS, not significantly different from "No" value (P > 0.05).

 
We next addressed whether expression levels of the splice variants were altered by cytokine treatment. Treatment of fibroblasts with 1 ng/ml IL-1{beta} for 8 h or 50 ng/ml TNF-{alpha} for 24 h increased the levels of all three variants (Fig. 4B). However, quantification of band intensities revealed that cytokine treatment increased the amount of the exon 1-3 variant (IL-1{beta}, 3.6x; TNF-{alpha}, 3.2x) more than the exon 1-2-3 variants (IL-1{beta}, 2.8x; TNF-{alpha}, 2.7x). When expressed as a ratio to minimize variations between different explants of primary fibroblasts, this effect was significant with IL-1{beta} but not quite significant with TNF-{alpha} (Fig. 4C). Because of its minor contribution and the difficulty of cleanly separating it, the exon 1-2-3+6 variant was amalgamated with exon 1-2-3 in these quantifications. Therefore, in addition to increasing transcription of all variants, IL-1{beta} treatment (and TNF-{alpha} to a lesser extent) altered posttranscriptional splicing of AT1A, with the smaller variant increasing more than the larger variants.

Rat AT1A exon 1-3 splice variant is translated more efficiently. The human AT1 gene contains a minicistron that has been shown previously to inhibit translation of downstream ORFs (6). Sequence analysis of rat AT1A mRNA also revealed a minicistron with an optimal start codon (encoding a seven-amino acid polypeptide) that was contained entirely within exon 2. Thus the rat exon 1-3 transcript might be translated more efficiently than the exon 1-2-3 and exon 1-2-3+6 transcripts. To test this hypothesis, the 5' UTRs of the three AT1A splice variants were amplified by RT-PCR and inserted individually into the 5' UTR of a luciferase reporter gene (Fig. 5A). Normalized luciferase activity from 293A cells transfected with the exon 1-2-3 construct was ~26% lower than that with the exon 1-3 construct (Fig. 5B). This inhibition of luciferase biosynthesis observed with exon 1-2-3 was caused by the exon 2 minicistron, since removal of both minicistron start codons by site-directed mutagenesis restored full luciferase activity (Fig. 5B, Mut-1-2-3 bar). The exon 1-2-3+6 construct demonstrated reduced luciferase activity that was more pronounced than that of exon 1-2-3 (Fig. 5B). This effect is likely caused by the added presence of an inhibitory stem-loop structure at the exon 2-exon 3 boundary that was predicted recently by Zhang et al. (39); this possibility is discussed in more detail (see DISCUSSION). These data support the hypothesis that the exon 2 minicistron, when present in the 5' UTR of a mRNA, can lower translation efficiency by competing with the downstream start site of the protein's ORF. This competition occurs even in the presence of the strong Kozak consensus sequence (i.e., GCCACCATGG) that exists in the luciferase gene of pGL3-Promoter. Thus the AT1A 1-3 variant is expected to produce more AT1A protein per unit of mRNA than the 1-2-3 or 1-2-3+6 variant. In addition, the 1-2-3 variant is expected to produce more protein per unit of mRNA than the 1-2-3+6 variant.


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
These studies were designed to investigate the mechanisms involved in cytokine-induced upregulation of AT1A receptors. Our results demonstrating increased hnRNA levels suggest that mRNA upregulation occurs transcriptionally. To further elucidate the role of NF-{kappa}B in transcriptional regulation of AT1, we searched the known AT1A promoter region for potential NF-{kappa}B binding sites. Two potential sites were identified and were verified to bind NF-{kappa}B. In addition, three splice variants of AT1A mRNA were found in rat cardiac fibroblasts and all other rat tissue tested. Cytokine treatment of cardiac fibroblasts upregulated all splice variants with the smallest variant (i.e., 1-3) increasing to the greatest degree. This smaller splice variant appeared to be translated more efficiently due to the absence of an inhibitory minicistron in exon 2. Thus our results provide additional information regarding the upregulation of AT1A receptors by proinflammatory cytokines. Both IL-1{beta} and TNF-{alpha} can increase AT1A receptor levels mainly by increasing transcription but also by modifying splicing to enhance translation of the resulting mRNA.

Previous results showing that TNF-{alpha} does not increase the stability of AT1A mRNA in neonatal rat cardiac fibroblasts (11) and that the transcription factor NF-{kappa}B was necessary for TNF-{alpha}- and IL-1{beta}-induced upregulation of AT1 mRNA (4) suggested that the mechanism of upregulation was transcriptional. To provide additional support for this, RT-PCR was used to demonstrate that both AT1A hnRNA and mRNA were upregulated by exposure to cytokines. Although hnRNA levels can increase via enhanced nuclear stability, increased hnRNA usually reflects increased transcription and has been used as a substitute for nuclear runoff (8, 14). These results provided sufficient evidence to warrant a more detailed study of the effects of cytokines on AT1A transcription. Computer analysis of the rat AT1A promoter region identified two putative NF-{kappa}B binding sites at –365 and –2540 bp. These sites were verified to bind NF-{kappa}B by EMSA and were shown to transactivate a minimal promoter using luciferase reporter assays. Therefore, both the –365- and –2540-bp sequences are functional as isolated sites, and either could be necessary for the NF-{kappa}B-dependent upregulation, although the –365-bp sequence appears to be a stronger candidate.

During RACE experiments to identify the promoter region used to initiate AT1A transcription in neonatal rat cardiac fibroblasts, three AT1A mRNA splice variants were detected. These variants involved the 5' UTR and differed in size by <90 bp, which explains why they were not seen previously with RT-PCR of the coding region (i.e., exon 3) or on Northern blots. Rat AT1A splice variants with and without exon 2 have been identified previously (16, 22, 39), but to our knowledge, exon 1-2-3 and exon 1-2-3+6 have not been recognized previously as unique transcripts. The human AT1 gene also possesses a single coding exon that is preceded by multiple exons comprising the 5' UTR. In humans, four alternatively spliced mRNAs have been identified (19). Human exon 3 has an inframe start codon that can produce a long receptor isoform with a greater than threefold diminished affinity for ANG II (6, 19), but this does not occur in the rat gene. However, like rats, human exon 2 contains a minicistron that reduces translational efficiency of the AT1 coding sequence (6). In both humans and rats, alternative splicing of the 5' UTR may provide an additional mechanism to control expression of the AT1 receptor protein. Conservation between species of this alternative splicing and its effect on translation suggests that it plays an important role in AT1 expression.

During the final writing of this article, Ji et al. (16) and Zhang et al. (39) published studies that analyzed the translational regulation of rat AT1A by sequences within its 5' UTR. They concluded that translation is reduced by the presence of four upstream AUGs, two in exon 1 and two in exon 2, and also by a predicted hairpin structure that involves the exon 2-exon 3 boundary. Although they influence translational efficiency, the two AUGs in exon 1 are present in all transcripts and are not removed by alternative splicing. Inhibition of translation by the two AUGs within exon 2 is consistent with our findings. Upon further examination, the six extra nucleotides in 1-2-3+6 are integral to the stem of the predicted hairpin in exon 2. It is expected, therefore, that variant 1-2-3+6 will possess this hairpin, whereas 1-2-3 will not. This explains why the 1-2-3+6 5' UTR produced a greater reduction of luciferase activity (Fig. 5B), since it possesses both the exon 2 minicistron and hairpin.

Although the exon 1-2-3 splice variant predominated in most rat tissues analyzed, the relative level of the exon 1-3 variant could be increased by cytokine treatment. Nogues et al. (24) concluded that exon skipping correlated positively with the efficiency with which RNA polymerase II reached the 3' end of a gene. Increased transcriptional elongation or processivity of the rat AT1A gene could result in increased skipping of exon 2. NF-{kappa}B is known to stimulate transcription of genes by histone acetyltransferase recruitment (31), but it has also been shown to stimulate transcriptional elongation (36). Therefore, cytokine-induced increases in AT1A transcription and alterations in its splicing both may be related to NF-{kappa}B activation. We have found in cardiac fibroblasts that IL-1{beta} produces a greater increase in the initial rate of NF-{kappa}B-dependent transcription than does TNF-{alpha} (10). This observation is in agreement with the findings in the present article, since IL-1{beta} treatment led to more skipping of AT1A exon 2 than did TNF-{alpha} (see Fig. 4C).

We have shown previously that the inflammatory cytokines TNF-{alpha} and IL-1{beta} upregulate AT1A mRNA and protein in cultured neonatal rat cardiac fibroblasts (11). Both inflammatory cytokines and increased AT1 receptor density are found in the post-MI hearts of animal models and humans (10, 15, 18, 25, 26). These findings suggest that TNF-{alpha} and/or IL-1{beta} present in vivo in post-MI hearts are responsible for the observed upregulation of AT1 receptors. Receptor upregulation induced by these cytokines in cultured fibroblasts enhances [3H]proline incorporation and tissue inhibitor of metalloproteinase-1 (TIMP-1) protein production and reduces matrix metalloproteinase-2 (MMP-2) levels upon ANG II stimulation (27). These findings suggest that increased AT1 receptor levels enhance ANG II-mediated functions favoring ECM deposition. Inflammatory cytokines such as TNF-{alpha} can directly stimulate ECM degradation (27, 32), but through AT1 upregulation, for example, they may facilitate subsequent events that lead to ECM deposition. Studying the mechanism(s) of cytokine-induced AT1 upregulation in cultured neonatal rat cardiac fibroblasts should help improve understanding of how fibroblasts modulate their activity within the environment of post-MI hearts. The present studies show that proinflammatory cytokines increase AT1 receptor expression mainly by increasing transcription but also by altering mRNA splicing. These results extend our previous findings that NF-{kappa}B activation is necessary for cytokine-induced AT1 transcription by demonstrating binding sites in the promoter region. Inhibition of NF-{kappa}B activation either by interruption of binding to these sites or by disruption of signaling pathways (4) could be exploited as a therapeutic approach to modify AT1 receptor expression in certain circumstances.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by an American Heart Association Western States Affiliate Postdoctoral Fellowship (to R. T. Cowling) and National Institutes of Health Grant 1 R01 HL-63909 (to B. H. Greenberg). V. C. Reese was supported by National Heart, Lung, and Blood Institute Grant T35 HL-067694 to the University of California Medical Scientist Training Program Summer Undergraduate Research Fellowship. DNA sequencing was funded in part by National Cancer Institute Cancer Center Support Grant 2 P30 CA-23100-18.


   ACKNOWLEDGMENTS
 
The authors thank Van Tran and Cristina Moore for technical assistance and Dr. Christopher K. Glass for helpful comments.

Present address for V. C. Reese: Brown University, Providence, RI 02912.


   FOOTNOTES
 

Address for reprint requests and other correspondence: B. Greenberg, Univ. of California, San Diego, 200 West Arbor Dr., San Diego, CA 92103-8411 (E-mail: bgreenberg{at}ucsd.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, and Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89: 151–163, 1994.[Abstract/Free Full Text]
  2. Burlew BS and Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 18: 435–442, 2000.[CrossRef][Medline]
  3. Clauser E, Curnow KM, Davies E, Conchon S, Teutsch B, Vianello B, Monnot C, and Corvol P. Angiotensin II receptors: protein and gene structures, expression and potential pathological involvements. Eur J Endocrinol 134: 403–411, 1996.[Abstract/Free Full Text]
  4. Cowling RT, Gurantz D, Peng J, Dillmann WH, and Greenberg BH. Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta. J Biol Chem 277: 5719–5724, 2002.[Abstract/Free Full Text]
  5. Curnow KM. Human type-1 angiotensin II (AT1) receptor gene structure and function. Clin Exp Pharmacol Physiol Suppl 3: S67–S73, 1996.[Medline]
  6. Curnow KM, Pascoe L, Davies E, White PC, Corvol P, and Clauser E. Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. Mol Endocrinol 9: 1250–1262, 1995.[Abstract/Free Full Text]
  7. De Carvalho FC, Sun Y, and Weber KT. Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 129: 439–446, 1997.[CrossRef][Web of Science][Medline]
  8. Delany AM. Measuring transcription of metalloproteinase genes. Nuclear run-off assay vs. analysis of hnRNA. Methods Mol Biol 151: 321–333, 2001.[Medline]
  9. Guo DF, Uno S, Ishihata A, Nakamura N, and Inagami T. Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter. Circ Res 77: 249–257, 1995.[Abstract/Free Full Text]
  10. Gurantz D, Cowling RT, Varki N, Fricovsky E, Moore CD, and Greenberg BH. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 38: 505–515, 2005.[CrossRef][Web of Science][Medline]
  11. Gurantz D, Cowling RT, Villarreal FJ, and Greenberg BH. Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts. Circ Res 85: 272–279, 1999.[Abstract/Free Full Text]
  12. Gyurko R, Kimura B, Kurian P, Crews FT, and Phillips MI. Angiotensin II receptor subtypes play opposite roles in regulating phosphatidylinositol hydrolysis in rat skin slices. Biochem Biophys Res Commun 186: 285–292, 1992.[CrossRef][Web of Science][Medline]
  13. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, Podkolodny NL, and Kolchanov NA. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362–367, 1998.[Abstract/Free Full Text]
  14. Herman JP, Schafer MK, Watson SJ, and Sherman TG. In situ hybridization analysis of arginine vasopressin gene transcription using intron-specific probes. Mol Endocrinol 5: 1447–1456, 1991.[Abstract/Free Full Text]
  15. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, and Liu P. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 99: 1492–1498, 1999.[Abstract/Free Full Text]
  16. Ji H, Zhang Y, Zheng W, Wu Z, Lee S, and Sandberg K. Translational regulation of angiotensin type 1a receptor expression and signaling by upstream AUGs in the 5' leader sequence. J Biol Chem 279: 45322–45328, 2004.[Abstract/Free Full Text]
  17. Lee AA, Dillmann WH, McCulloch AD, and Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 27: 2347–2357, 1995.[CrossRef][Web of Science][Medline]
  18. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RA, Suzuki T, Morgan K, Polak JM, and Poole-Wilson PA. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol 28: 429–440, 1996.[CrossRef][Web of Science][Medline]
  19. Martin MM, Willardson BM, Burton GF, White CR, McLaughlin JN, Bray SM, Ogilvie JW Jr, and Elton TS. Human angiotensin II type 1 receptor isoforms encoded by messenger RNA splice variants are functionally distinct. Mol Endocrinol 15: 281–293, 2001.[Abstract/Free Full Text]
  20. Milavetz JJ, Raya TE, Johnson CS, Morkin E, and Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 27: 714–719, 1996.[Abstract]
  21. Murasawa S, Matsubara H, Urakami M, and Inada M. Regulatory elements that mediate expression of the gene for the angiotensin II type 1a receptor for the rat. J Biol Chem 268: 26996–27003, 1993.[Abstract/Free Full Text]
  22. Murphy TJ, Alexander RW, Griendling KK, Runge MS, and Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351: 233–236, 1991.[CrossRef][Medline]
  23. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, and Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92: 10663–10667, 1995.[Abstract/Free Full Text]
  24. Nogues G, Kadener S, Cramer P, Bentley D, and Kornblihtt AR. Transcriptional activators differ in their abilities to control alternative splicing. J Biol Chem 277: 43110–43114, 2002.[Abstract/Free Full Text]
  25. Ohtani S, Fujiwara H, Hasegawa K, Doyama K, Inada T, Tanaka M, Fujiwara T, and Sasayama S. Up-regulated expression of angiotensin II type 1 receptor gene in human pathologic hearts. J Card Fail 3: 303–310, 1997.[CrossRef][Medline]
  26. Ono K, Matsumori A, Shioi T, Furukawa Y, and Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98: 149–156, 1998.[Abstract/Free Full Text]
  27. Peng J, Gurantz D, Tran V, Cowling RT, and Greenberg BH. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 91: 1119–1126, 2002.[Abstract/Free Full Text]
  28. Pfeffer JM, Pfeffer MA, and Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57: 84–95, 1985.[Abstract/Free Full Text]
  29. Rodrigues EJ, Eisenberg MJ, and Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 115: 473–479, 2003.[CrossRef][Web of Science][Medline]
  30. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, and Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 72: 1245–1254, 1993.[Abstract/Free Full Text]
  31. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, and Collins T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19: 6367–6378, 1999.[Abstract/Free Full Text]
  32. Siwik DA, Chang DL, and Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86: 1259–1265, 2000.[Abstract/Free Full Text]
  33. Sun Y, Ramires FJ, and Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 35: 138–147, 1997.[Abstract/Free Full Text]
  34. Takeuchi K, Alexander RW, Nakamura Y, Tsujino T, and Murphy TJ. Molecular structure and transcriptional function of the rat vascular AT1a angiotensin receptor gene. Circ Res 73: 612–621, 1993.[Abstract/Free Full Text]
  35. Villarreal FJ, Kim NN, Ungab GD, Printz MP, and Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88: 2849–2861, 1993.[Abstract/Free Full Text]
  36. West MJ, Lowe AD, and Karn J. Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 75: 8524–8537, 2001.[Abstract/Free Full Text]
  37. Wollert KC, Studer R, von Bulow B, and Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation 90: 2457–2467, 1994.[Abstract/Free Full Text]
  38. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, and Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 25: 1369–1380, 1993.[CrossRef][Web of Science][Medline]
  39. Zhang Y, Ji H, Elena FM, Falconetti C, Zheng W, and Sandberg K. Translational control of the rat angiotensin type 1a receptor by alternative splicing. Gene 341: 93–100, 2004.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
 Circ. Res.Home page
C. A. Souders, S. L.K. Bowers, and T. A. Baudino
Cardiac Fibroblast: The Renaissance Cell
Circ. Res., December 4, 2009; 105(12): 1164 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. A. Banday and M. F. Lokhandwala
Loss of Biphasic Effect on Na/K-ATPase Activity by Angiotensin II Involves Defective Angiotensin Type 1 Receptor-Nitric Oxide Signaling
Hypertension, December 1, 2008; 52(6): 1099 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. A. Banday and M. F. Lokhandwala
Oxidative stress-induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F698 - F706.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. Petnehazy, D. Cooper, K. Y. Stokes, J. Russell, K. C. Wood, and D. N. Granger
Angiotensin II type 1 receptors and the intestinal microvascular dysfunction induced by ischemia and reperfusion
Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1203 - G1210.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/3/H1176    most recent
00088.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cowling, R. T.
Right arrow Articles by Greenberg, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cowling, R. T.
Right arrow Articles by Greenberg, B. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.